1. Ganz PA, Gotay CC. Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions. J Clin Oncol 2007; 25 (32): 5063–9.
2. Sloan JA, Berk L, Roscoe J et al. Dueck Integrating Patient-Reported Outcomes Into Cancer Symptom Management Clinical Trials Supported by the National Cancer Institute–Sponsored Clinical Trials Networks. J Clin Oncol 2007; 25 (32): 5070–7.
3. Bottomley A, Neil K. Aaronson International Perspective on Health-Related Quality-of-Life Research in Cancer Clinical Trials: The European Organisation for Research and Treatment of Cancer Experience. J Clin Oncol 2007; 25 (32): 5082–6.
4. Gondek K, Sagnier P-P, Gilchrist K, Woolley JM. Current Status of Patient-Reported Outcomes in Industry-Sponsored Oncology Clinical Trials and Product Labels. J Clin Oncol 2007; 25 (32): 5087–93.
5. Rock EP, Kennedy DL, Furness MH et al. Burke Patient-Reported Outcomes Supporting Anticancer Product Approvals. J Clin Oncol 2007; 25 (32): 5094–9.
6. Новик А.А., Ионова Т.И., Кайнд П. Концепция исследования качества жизни в медицине. СПб.: Элби, 1999.
7. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. СПб.: ОЛМА-ПРЕСС Звездный мир, 2002.
8. Rizzo D, Lichtin A, Woolf S et al. Use of Epoetin in Patients with Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20 (19): 4083–107.
9. Osterborg A, Brandberg Y, Molostova V et al. Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486–94.
10. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 1998; 15 (suppl. 1): 19–28.
11. Oberhof C, Neri B, Amadori D et al. Recombinant human erythoropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9: 255–60.
12. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of reponse. Blood 1995; 86: 1676–8.
13. Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003; 88: 988–95.
14. Cazzola M, Coiffier B, Kloczko J et al. Predictors of hemoglobin response in patients with lymphoid tumors –results of the NOW (NeoRecormon Once Weekly) study (abstract no.0185). Proceedings of the 7th Annual Meeting of the European hematology Association (EHA); 6–9 June 2002, Florence, Italy.
15. Новик А.А., Ионова Т.И., Мезенова Т.В. и др. Cистемный мониторинг состояния больных ревматоидным артритом: клинический ответ и ответ, связанный с качеством жизни. Вестн. Межнацион. центра исследования качества жизни. 2005; 5–6: 17–26.

А.А.Новик1, Т.И.Ионова2, В.Л.Иванова3, Д.П.Удовица4, К.М.Абдулкадыров5, А.Б.Бакиров6, В.Ф.Ачикян7

1 Национальный медико-хирургический центр им. Н.И.Пирогова, Москва;
2 Северо-Западный окружной медицинский центр МЗСР РФ, Санкт-Петербург;
3 Городская клиническая больница им. С.П.Боткина, Москва;
4 МУЗ Онкологический диспансер, Сочи;
5 НИИ гематологии и трансфузиологии Росздрава, Санкт-Петербург;
6 Республиканская клиническая больница им. Г.Г.Куватова, Уфа;
7 Ф.Хоффманн-Ля Рош Лтд., Базель, Представительство в Москве